|
イマイ カズオ
IMAI Kazuo
今井 一男 所属 埼玉医科大学 医学部 臨床検査医学（中央検査部） 職種 専任講師 |
|
| 論文種別 | 学術雑誌(原著) |
| 言語種別 | 英語 |
| 査読の有無 | 査読なし |
| 表題 | Clinical characteristics and antibody response to SARS-CoV-2 spike 1 protein using VITROS Anti-SARS-CoV-2 antibody tests in COVID-19 patients in Japan. |
| 掲載誌名 | 正式名：Journal of medical microbiology |
| 巻・号・頁 | 70(4) |
| 著者・共著者 | Mayu Nagura-Ikeda,Kazuo Imai,Katsumi Kubota,Sakiko Noguchi,Yutaro Kitagawa,Masaru Matsuoka,Sakiko Tabata,Kazuyasu Miyoshi,Toshimitsu Ito,Kaku Tamura,Takuya Maeda |
| 発行年月 | 2021/04 |
| 概要 | Introduction. Serological tests for COVID-19 are important in providing results for surveillance and supporting diagnosis. Investigating the serological response in COVID-19 patients with different disease severity is important for assessing the clinical utility of serological assays.Gap Statement. However, few studies have investigated the clinical utility of antibody assays for COVID-19 or differences in antibody response in association with disease severity.Aim. The study aimed to evaluate the clinical characteristics and clinical utility of VITROS SARS-CoV-2 antibody tests according to COVID-19 severity in patients in Japan.Methodology. We analysed 255 serum specimens from 130 COVID-19 patients and examined clinical records and laboratory data. Presence of total (IgA, IgM, and IgG) and specific IgG antibody for the spike 1 antigen of SARS-CoV-2 was determined using VITROS Anti-SARS-CoV-2 antibody tests.Results. Overall, 98 (75.4 %) and 32 (24.6 %) patients had mild and severe COVID-19, respectively. On admission, 76 (58.5 %) and 45 (34.6 %) patients were positive for total and IgG antibody assays. Among 91 patients at discharge, 90 (98.9 %) and 81 (89.0 %) were posi |
| DOI | 10.1099/jmm.0.001291 |
| PMID | 33861191 |